Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit Jan Schuurhuis(Amsterdam UMC Location Vrije Universiteit Amsterdam), Gert J. Ossenkoppele(Amsterdam UMC Location Vrije Universiteit Amsterdam), Gail J. Roboz(Cornell University), Francis Lacombe, Roland B. Walter(University of Washington), Brent L. Wood(University of Washington), Claude Preudhomme(Centre National de la Recherche Scientifique), Sylvie Freeman(University of Birmingham), Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Luca Maurillo(University of Rome Tor Vergata), Torsten Haferlach(Munich Leukemia Laboratory (Germany)), Robert K. Hills(Cancer Research UK Clinical Trials Unit), Bert A. van der Reijden(Erasmus University Rotterdam), Michael Heuser(Medizinische Hochschule Hannover), Konstanze Döhner(University Hospital Ulm), Christopher S. Hourigan(Institute of Cancer Research), Marie C. Béné(Centre Hospitalier Universitaire de Nantes), Jacqueline Cloos(Amsterdam University Medical Centers), Paresh Vyas(John Radcliffe Hospital), David Grimwade(University of Cambridge), Francesco Buccisano(University of Rome Tor Vergata), Adriano Venditti(University of Rome Tor Vergata), Christian Thiede(Klinik und Poliklinik für Psychotherapie und Psychosomatik)
Cited by 1,026
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k